Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus

Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus

This article addresses possible mechanisms for development of cardiovascular events (CVE) in type 2 diabetes mellitus (T2DM) patients treated with sulfonylurea derivatives (SU). Several problems are highlighted in this review, including molecular aspects of pancreatic and extrapancreatic action of t...

Full description

Bibliographic Details
Main Author:	Lyudmila Viktorovna Nedosugova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2013-06-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus sulfonylureas sur katp channel ischemic preconditioning
Online Access:	https://dia-endojournals.ru/dia/article/viewFile/3753/1929

Similar Items

Sulfonylureas in the modern strategy of therapy of type 2 diabetes
by: Lyudmila Viktorovna Nedosugova
Published: (2011-06-01)

Glibenclamide - profile of efficacy and safety
by: Lyudmila Viktorovna Nedosugova
Published: (2011-09-01)

Ligand binding and conformational changes of SUR1 subunit in pancreatic ATP-sensitive potassium channels
by: Jing-Xiang Wu, et al.
Published: (2018-03-01)

The place of the third generation sulfonylurea glimepiride in modern therapy of type 2 diabetes mellitus
by: L.V. Zhuravlyova, et al.
Published: (2019-03-01)

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
by: Alla Vsevolodovna Rudakova
Published: (2011-09-01)

Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications
by: Chiedozie Kenneth Ugwoke, et al.
Published: (2017-01-01)

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
by: Yeoree Yang, et al.
Published: (2016-10-01)

Sulfonylurea and neuroprotection: The bright side of the moon
by: Nawar R Hussien, et al.
Published: (2018-01-01)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
by: Se Hee Min, et al.
Published: (2015-12-01)

Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus
by: O N Goncharenko, et al.
Published: (2012-08-01)

Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea
by: Kunavisarut T, et al.
Published: (2019-05-01)

Exploring the role and inter-relationship among nitric oxide, opioids, and KATP channels in the signaling pathway underlying remote ischemic preconditioning induced cardioprotection in rats
by: Sapna Aggarwal, et al.
Published: (2019-07-01)

Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial
by: Seung-Eun Lee, et al.
Published: (2019-08-01)

Hydrogen sulfide-mediated cardioprotection against ischemia reperfusion is linked to KATP channel for mitochondrial preservation but not for its distinct preference on interfibrillar mitochondria
by: Priyadharshini Chandrasekaran, et al.
Published: (2019-06-01)

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
by: Sanjay Kalra, et al.
Published: (2015-01-01)

The frequency of hypoglycemia and cardiovascular disorders during therapy with sulfonylureas compared with other secretagogues: a systematic review
by: Aleksey Vadimovich Zilov, et al.
Published: (2010-06-01)

Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel mutation
by: Sung Yeon Ahn, et al.
Published: (2015-08-01)

ATP-sensitive potassium channel subcellular trafficking during ischemia, reperfusion, and preconditioning
by: Ho, Joanne Cin-Yee
Published: (2016)

Prevalence of Hypoglycemia, Treatment Satisfaction, Adherence and Their Associations with Glycemic Goals in Patients with Type 2 Diabetes Mellitus Treated with Sulfonylureas: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) in Romania
by: Popoviciu Simona, et al.
Published: (2019-03-01)

Feasibility of efficacious therapy of diabetes mellitus by sulfonylurea agents in neonates with KCNJII gene mutation: originalobservation
by: Andrey Olegovich Emel'yanov, et al.
Published: (2009-09-01)

Association among insulin receptor substrate1 genetic polymorphism, sulfonylurea therapeutic efficacy, and insulin resistance in patients with type 2 diabetes mellitus
by: Ghada A Omar, et al.
Published: (2021-01-01)

Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study
by: Po-Chung Cheng, et al.
Published: (2019-10-01)

TREATMENT OF THE TYPE 2 OF DIABETES PATIENTS WITH THE SECONDARY FAILURE OF THE ORAL THERAPY: COMPARISON OF THE INSULIN-SULFONYLUREA REGIME AND THAT OF THE INSULIN-METFORMIN
by: Saša Živić, et al.
Published: (2002-09-01)

Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01)

Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol
by: Dennis Schrijnders, et al.
Published: (2017-06-01)

Neonatal diabetes and congenital hyperinsulinism caused by mutations in ABCC8/SUR1 are associated with altered and opposite affinities for ATP and ADP
by: Joseph eBryan, et al.
Published: (2015-04-01)

Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective
by: Alper Gümüş, et al.
Published: (2019-03-01)

Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in
by: Jong Seo Yoon, et al.
Published: (2018-09-01)

A novel mutation KCNJ11 R136C caused KCNJ11-MODY
by: Yaning Chen, et al.
Published: (2021-08-01)

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
by: Hassoun AAK, et al.
Published: (2016-07-01)

Role of mitochondrial ATP-sensitive potassium channel-mediated PKC-ε in delayed protection against myocardial ischemia/reperfusion injury in isolated hearts of sevoflurane-preconditioned rats
by: C. Wang, et al.
Published: (2015-06-01)

REDUCTION OF CARDIOVASCULAR COMPLICATIONS OF MODERN HYPOGLYCEMIC THERAPY OF DIABETES MELLITUS TYPE 2: "FLORENTINE HERESY"
by: A. A. Aleksandrov
Published: (2016-01-01)

Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone
by: Luxi Yang, et al.
Published: (2021-09-01)

Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial - START Study
by: T V Devarajan, et al.
Published: (2017-01-01)

Insulinoma Causing Hypoglycemia in a Patient with Type 2 Diabetes
by: Wei-Yi Lei, et al.
Published: (2007-05-01)

Transcription factor 7-like 2 rs7903146 polymorphism and therapeutic response to sulfonylureas in patients with type 2 diabetes
by: Ghada A Omar, et al.
Published: (2018-01-01)

MODY3 in the child with type 2 diabetes mellitus phenotype: case report
by: Tamara Leonidovna Kuraeva, et al.
Published: (2013-06-01)

Biophysical Studies of the First Nucleotide Binding Domain of SUR2A
by: de Araujo, Elvin Dominic
Published: (2011)

Domain Boundaries are Essential for the Solubility of Nucleotide Binding Domains of ABC Transporters
by: Ikeda, Lynn Kumiko
Published: (2010)

Cannot write session to /tmp/vufind_sessions/sess_nt8qvi2tf5081geb3q3k075rkb